The Future of Prefilled Syringes: Yes, There Are a Few Challenges

left hand static image

The Future of Prefilled Syringes: Yes, There Are a Few Challenges

As a pharma executive who has worked in companies that manufacture prefilled syringes (PFS), I have closely observed the production process for this format and have come to appreciate both the opportunities and the challenges they present to pharma companies and healthcare providers.

The manufacturer must optimize these processes to minimize the rejection rate. The development and overall manufacturing time tends to slow down. This, not surprisingly, adds to overall manufacturing expense, which in turn contributes to the higher cost of the PFS format for healthcare providers.

Beth Totin

CHIEF COMMERCIAL OFFICER

With 20+ years of experience in marketing and business development, Beth Totin has spearheaded the growth of BFS and traditional glass filling (PFS, vials and cartridge) manufacturing and commercialization efforts for several multinational contract manufacturing organizations.

Prior to joining ApiJect, Beth was responsible for the introduction of a new manufacturing facility in North America for Unither Pharmaceuticals (France), significantly scaling the site for sterile and oral product technologies. During her time at Siegfried, Beth directed innovation efforts around biologics and delivery devices through domestic and international production sites of glass ampoules, vials, cartridges, and BFS. At Catalent, she expanded the customer base by helping to create a new injectable BFS product offering while overseeing a domestic BFS manufacturing site and multiple international sites serving global customers.